$CRXT - Patent Granted, Still Time to Get In on Clarus with a Price Target of 10

CRTX was granted a US patent for “Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same”. Sometimes catalysts don’t come in the form of formal news releases. Based on this, it’s essential to have your ear to the ground and pay close attention to anything that could impact certain companies. When we talk about biotech, everything from FDA decisions to patent updates can affect a stock. Clarus was moving thanks to this patent news. Here are some of the details that emerged early on but have yet to be formally reported in a company press release. For complete information from the US Patent and Trademark Office, you can follow this link: The abstract of the patent states that this is: A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided. There are 27 claims listed in the full patent notice on the USPTO site. According to the patent, the field of the invention is described as “The present invention relates generally to oral formulations of testosterone esters for the treatment of testosterone deficiency. More particularly, the present invention relates to pharmaceutical composition comprising testosterone undecanoate (TU) with enhanced and extended absorption and pharmacokinetics.” This patent news comes just a few days after Clarus reported its 3rd quarter 2021 results. Included in the highlights was mention of significant prescription growth for JATENZO. The company recorded 12% sequential growth and more than 130% growth year-over-year. I think there is still time to enter this position - even after the big run up today Truist joined Needham, Maxim, Oppenheimer, and Cantor Fitzgerald, all having a Buy or equivalent and price targets ranging from $12 to $20. Furthermore, with a total outstanding share count of less than 22 million right now Will be looking for an entry point and will dive deeper into the company so keep an eye out for updates to this analysis